Int J Stem Cells.  2016 May;9(1):137-144. 10.15283/ijsc.2016.9.1.137.

Severe Type 2 Diabetes Induces Reversible Modifications of Endothelial Progenitor Cells Which are Ameliorate by Glycemic Control

• De Pascale MR
• Bruzzese G
• Crimi E
• Grimaldi V
• Liguori A
• Brongo S
• Barbieri M
• Picascia A
• Schiano C
• Sommese L
• Ferrara N
• Paolisso G
• Napoli C

• KMID: 2164170
• DOI: http://doi.org/10.15283/ijsc.2016.9.1.137

Abstract

BACKGROUND
Circulating endothelial progenitors cells (EPCs) play a critical role in neovascularization and endothelial repair. There is a growing evidence that hyperglycemia related to Diabetes Mellitus (DM) decreases EPC number and function so promoting vascular complications. AIM OF THE STUDY: This study investigated whether an intensive glycemic control regimen in Type 2 DM can increase the number of EPCs and restores their function.
METHODS
Sixty-two patients with Type 2 DM were studied. Patients were tested at baseline and after 3 months of an intensive regimen of glycemic control. The Type 2 DM group was compared to control group of subjects without diabetes. Patients with Type 2 DM (mean age 58.2±5.4 years, 25.6% women, disease duration of 15.4±6.3 years) had a baseline HgA1c of 8.7±0.5% and lower EPC levels (CD34+/KDR+) in comparison to healthy controls (p<0.01).
RESULTS
The intensive glycemic control regimen (HgA1c decreased to 6.2±0.3%) was coupled with a significant increase of EPC levels (mean of 18%, p<0.04 vs. baseline) and number of EPCs CFUs (p<0.05 vs. baseline).
CONCLUSION
This study confirms that number and bioactivity of EPCs are reduced in patients with Type 2 DM and, most importantly, that the intensive glycemic control in Type 2 DM promotes EPC improvement both in their number and in bioactivity.

Keyword

Type 2 diabetes; Endothelial progenitor cells; Vascular disease; Regenerative medicine

MeSH Terms

Diabetes Mellitus
Female
Humans
Hyperglycemia
Regenerative Medicine
Stem Cells*
Vascular Diseases

Figure

• 

  Fig. 1 Number of EPCs positive to FACS and EPCs positive to chemotaxic assay for VEGF-A in healthy group vs type 2 DM patients pre- and after glycemic control.

Reference

References

1. Sommese L, Vasco M, Costa D, Napoli C. Endothelial progenitor cells and human diseases. Ann Hematol. 2014; 93:533–534. DOI: 10.1007/s00277-013-1840-z.

2. Napoli C, Hayashi T, Cacciatore F, Casamassimi A, Casini C, Al-Omran M, Ignarro LJ. Endothelial progenitor cells as therapeutic agents in the microcirculation: an update. Atherosclerosis. 2011; 215:9–22. DOI: 10.1016/j.atherosclerosis.2010.10.039.

3. Wojakowski W, Kucia M, Kaźmierski M, Ratajczak MZ, Tendera M. Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism? Heart. 2008; 94:27–33. DOI: 10.1136/hrt.2006.103358.

4. Liguori A, Fiorito C, Balestrieri ML, Crimi E, Bruzzese G, Williams-Ignarro S, D’Amora M, Sommese L, Grimaldi V, Minucci PB, Giovane A, Farzati B, Ignarro LJ, Napoli C. Functional impairment of hematopoietic progenitor cells in patients with coronary heart disease. Eur J Haematol. 2008; 80:258–264. DOI: 10.1111/j.1600-0609.2007.01007.x.

5. Valgimigli M, Rigolin GM, Fucili A, Porta MD, Soukhomovskaia O, Malagutti P, Bugli AM, Bragotti LZ, Francolini G, Mauro E, Castoldi G, Ferrari R. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation. 2004; 110:1209–1212. DOI: 10.1161/01.CIR.0000136813.89036.21. PMID: 15249502.

6. King TF, McDermott JH. Endothelial progenitor cells and cardiovascular disease. J Stem Cells. 2014; 9:93–106. PMID: 25158158.

7. Grimaldi V, Mancini FP, Casamassimi A, Al-Omran M, Zullo A, Infante T, Napoli C. Potential benefits of cell therapy in coronary heart disease. J Cardiol. 2013; 62:267–276. DOI: 10.1016/j.jjcc.2013.05.017. PMID: 23834957.

8. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol. 2005; 39:733–742. DOI: 10.1016/j.yjmcc.2005.07.003. PMID: 16199052.

9. Cheng Z, Jiang X, Pansuria M, Fang P, Mai J, Mallilankaraman K, Gandhirajan RK, Eguchi S, Scalia R, Madesh M, Yang X, Wang H. Hyperhomocysteinemia and hyper-glycemia induce and potentiate endothelial dysfunction via μ-calpain activation. Diabetes. 2015; 64:947–959. DOI: 10.2337/db14-0784. PMCID: 4338586.

10. Tousoulis D, Papageorgiou N, Androulakis E, Siasos G, Latsios G, Tentolouris K, Stefanadis C. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol. 2013; 62:667–676. DOI: 10.1016/j.jacc.2013.03.089. PMID: 23948511.

11. de Nigris F, Rienzo M, Sessa M, Infante T, Cesario E, Ignarro LJ, Al-Omran M, Giordano A, Palinski W, Napoli C. Glycoxydation promotes vascular damage via MAPK-ERK/JNK pathways. J Cell Physiol. 2012; 227:3639–3647. DOI: 10.1002/jcp.24070. PMID: 22331607.

12. Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res. 2001; 49:554–560. DOI: 10.1016/S0008-6363(00)00228-5. PMID: 11166268.

13. Yiu KH, Tse HF. Specific role of impaired glucose metabolism and diabetes mellitus in endothelial progenitor cell characteristics and function. Arterioscler Thromb Vasc Biol. 2014; 34:1136–1143. DOI: 10.1161/ATVBAHA.114.302192. PMID: 24743430.

14. Nowak WN, Borys S, Kusińska K, Bukowska-Strakova K, Witek P, Koblik T, Józkowicz A, Małecki MT, Dulak J. Number of circulating pro-angiogenic cells, growth factor and anti-oxidative gene profiles might be altered in type 2 diabetes with and without diabetic foot syndrome. J Diabetes Investig. 2014; 5:99–107. DOI: 10.1111/jdi.12131. PMID: 24843745. PMCID: 4025239.

15. Westerweel PE, Teraa M, Rafii S, Jaspers JE, White IA, Hooper AT, Doevendans PA, Verhaar MC. Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus. PLoS One. 2013; 8:e60357. DOI: 10.1371/journal.pone.0060357. PMID: 23555959. PMCID: 3610687.

16. Desouza CV. Does drug therapy reverse endothelial progenitor cell dysfunction in diabetes? J Diabetes Complications. 2013; 27:519–525. DOI: 10.1016/j.jdiacomp.2013.04.007. PMID: 23809765.

17. Jiraritthamrong C, Kheolamai P, U-Pratya Y, Chayosumrit M, Supokawej A, Manochantr S, Tantrawatpan C, Sritanaudomchai H, Issaragrisil S. In vitro vessel-forming capacity of endothelial progenitor cells in high glucose conditions. Ann Hematol. 2012; 91:311–320. DOI: 10.1007/s00277-011-1300-6.

18. Yue WS, Lau KK, Siu CW, Wang M, Yan GH, Yiu KH, Tse HF. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2011; 10:113. DOI: 10.1186/1475-2840-10-113. PMID: 22185563. PMCID: 3258289.

19. António N, Fernandes R, Soares A, Soares F, Lopes A, Carvalheiro T, Paiva A, Pêgo GM, Providência LA, Gonçalves L, Ribeiro CF. Reduced levels of circulating endothelial progenitor cells in acute myocardial infarction patients with diabetes or pre-diabetes: accompanying the glycemic continuum. Cardiovasc Diabetol. 2014; 13:101. DOI: 10.1186/1475-2840-13-101. PMID: 24934236. PMCID: 4082424.

20. Pikkemaat M, Melander O, Mölstad S, Garberg G, Boström KB. C-peptide concentration, mortality and vascular complications in people with Type 2 diabetes. The Skaraborg Diabetes Register. Diabet Med. 2015; 32:85–89. DOI: 10.1111/dme.12608.

21. Kunz GA, Liang G, Cuculi F, Gregg D, Vata KC, Shaw LK, Goldschmidt-Clermont PJ, Dong C, Taylor DA, Peterson ED. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J. 2006; 152:190–195. DOI: 10.1016/j.ahj.2006.02.001. PMID: 16824855.

22. Fadini GP. A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. Diabetologia. 2014; 57:4–15. DOI: 10.1007/s00125-013-3087-6.

23. Westerweel PE, Teraa M, Rafii S, Jaspers JE, White IA, Hooper AT, Doevendans PA, Verhaar MC. Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus. PLoS One. 2013; 8:e60357. DOI: 10.1371/journal.pone.0060357. PMID: 23555959. PMCID: 3610687.

24. Saito H, Yamamoto Y, Yamamoto H. Diabetes alters subsets of endothelial progenitor cells that reside in blood, bone marrow, and spleen. Am J Physiol Cell Physiol. 2012; 302:C892–901. DOI: 10.1152/ajpcell.00380.2011.

25. Zhang J, Zhang X, Li H, Cui X, Guan X, Tang K, Jin C, Cheng M. Hyperglycaemia exerts deleterious effects on late endothelial progenitor cell secretion actions. Diab Vasc Dis Res. 2013; 10:49–56. DOI: 10.1177/1479164112444639.

26. Cubbon RM, Kahn MB, Wheatcroft SB. Effects of insulin resistance on endothelial progenitor cells and vascular repair. Clin Sci (Lond). 2009; 117:173–190. DOI: 10.1042/CS20080263.

27. Liguori A, Abete P, Hayden JM, Cacciatore F, Rengo F, Ambrosio G, Bonaduce D, Condorelli M, Reaven PD, Napoli C. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J. 2001; 22:2075–2084. DOI: 10.1053/euhj.2001.2655. PMID: 11686665.

28. Casamassimi A, Balestrieri ML, Fiorito C, Schiano C, Maione C, Rossiello R, Grimaldi V, Del Giudice V, Balestrieri C, Farzati B, Sica V, Napoli C. Comparison between total endothelial progenitor cell isolation versus enriched Cd133+ culture. J Biochem. 2007; 141:503–511. DOI: 10.1093/jb/mvm060. PMID: 17308344.

29. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275:964–967. DOI: 10.1126/science.275.5302.964. PMID: 9020076.

30. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol. 2005; 39:733–742. DOI: 10.1016/j.yjmcc.2005.07.003. PMID: 16199052.

31. Losordo DW, Kibbe MR, Mendelsohn F, Marston W, Driver VR, Sharafuddin M, Teodorescu V, Wiechmann BN, Thompson C, Kraiss L, Carman T, Dohad S, Huang P, Junge CE, Story K, Weistroffer T, Thorne TM, Millay M, Runyon JP, Schainfeld R. Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv. 2012; 5:821–830. DOI: 10.1161/CIRCINTERVENTIONS.112.968321. PMID: 23192920. PMCID: 3549397.

32. Churdchomjan W, Kheolamai P, Manochantr S, Tapanadechopone P, Tantrawatpan C, U-Pratya Y, Issaragrisil S. Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control. BMC Endocr Disord. 2010; 10:5. DOI: 10.1186/1472-6823-10-5. PMID: 20374643. PMCID: 2858721.

33. Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005; 111:2981–2987. DOI: 10.1161/CIRCULATIONAHA.104.504340. PMID: 15927972.

34. Sambataro M, Seganfreddo E, Canal F, Furlan A, Del Pup L, Niero M, Paccagnella A, Gherlinzoni F, Dei Tos AP. Prognostic significance of circulating and endothelial progenitor cell markers in type 2 diabetic foot. Int J Vasc Med. 2014; 2014:589412. PMID: 24624298. PMCID: 3929532.

35. Güven H, Shepherd RM, Bach RG, Capoccia BJ, Link DC. The number of endothelial progenitor cell colonies in the blood is increased in patients with angiographically significant coronary artery disease. J Am Coll Cardiol. 2006; 48:1579–1587. DOI: 10.1016/j.jacc.2006.04.101. PMID: 17045891.

36. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De Ferrari GM, Ferlini M, Goffredo L, Bertoletti A, Klersy C, Pecci A, Moratti R, Tavazzi L. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood. 2005; 105:199–206. DOI: 10.1182/blood-2004-05-1831.

37. Kotlinowski J, Dulak J, Józkowicz A. Type 2 diabetes mellitus impairs endothelial progenitor cells functions. Postepy Biochem. 2013; 59:257–266.

38. Pistrosch F, Herbrig K, Oelschlaegel U, Richter S, Passauer J, Fischer S, Gross P. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis. 2005; 183:163–167. DOI: 10.1016/j.atherosclerosis.2005.03.039. PMID: 15907852.

39. Raptis AE, Markakis KP, Mazioti MC, Ikonomidis I, Maratou EP, Vlahakos DV, Kotsifaki EE, Voumvourakis AN, Tsirogianni AG, Lambadiari VA, Lekakis JP, Raptis SA, Dimitriadis GD. Effect of aliskiren on circulating endothelial progenitor cells and vascular function in patients with type 2 diabetes and essential hypertension. Am J Hypertens. 2015; 28:22–29. DOI: 10.1093/ajh/hpu119.